 PITTSBURGH, March 30, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa DEB. Based on the timing of this milestone, Krystal expects to report top-line results from the study in the fourth quarter of 2021. 